Olorunseun “Seun” Ogunwobi, PhD
- Chair, Department of Biochemistry and Molecular Biology
- Department of Biochemistry and Molecular Biology
- Michigan State University College of Human Medicine
Bio
Olorunseun “Seun” Ogunwobi is the chair of the Department of Biochemistry and Molecular Biology and co-director of the Center for Cancer Health Equity Research at MSU.
Born and raised in Ibadan, Nigeria, Ogunwobi received his medical degree from the University of Ibadan, the top-ranked university in Nigeria and one of the best universities in Africa. He would go on to earn a master's degree in biomedicine from the University of Hull, United Kingdom; a master's degree in clinical and translational science from the University of Florida, Gainesville; and a PhD in molecular medicine from the University of East Anglia, Norwich, United Kingdom.
Ogunwobi was previously a professor of biology at the Hunter College of The City University of New York, founding director and principal investigator of the Hunter College Center for Cancer Health Disparities Research and an adjunct faculty member of the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine. He had been on the CUNY faculty since 2014.
His work has been funded by the National Institutes of Health, New York State, Carnegie Corporation of New York, and the National Science Foundation, among others. Ogunwobi is a Contact Principal Investigator of the Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH) funded by U54 grants CA221704 and CA221705, Contact Principal Investigator of 3U54CA221704-03S1, and Co-Investigator on R01 grant CA239603 from the National Cancer Institute. An author of over 70 peer-reviewed journal articles and two book chapters, Dr. Ogunwobi has been issued five U.S. patents for biotechnology inventions with potential clinical applications in cancer.
Ogunwobi is also the co-founder of two New York-based startup companies, UTR Therapeutics Inc., a pre-clinical stage biotech company with a first-in-class technology that can overwrite any target of interest; and NucleoBio Inc., a developer of diagnostics tools designed to detect non-invasive urological cancer. He is also a contact principal investigator of the Synergistic Partnership for Enhancing Equity in Cancer Health, or SPEECH, funded by a U54 grant from the National Cancer Institute.
Related
Department of Biochemistry and Molecular Biology
Center for Cancer Health Equity Research